The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

The NIH funding will help address a "traditional barrier" to health care, says Elizabeth Evans, professor of community health ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

There were still 32,000 new cases of HIV in the U.S. in 2022. And about thousands of people still die annually from AIDS. HIV ...

Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...

We finally have the technology, infrastructure, and the political will to end the US HIV epidemic, write the Brown University ...

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...

A University of Massachusetts Amherst public health researcher has received four grants totaling $17.9 million from the ...